RDY:NYSE
Dr Reddy's Laboratories Ltd
US$ 13,07
arrow_upward
+1,32%(+0,17) 1D
US$ 13,07
0,00% (0,00)
bedtimeNa sluitingstijd
Gesloten: 16 okt, 16:00:07 GMT-4 · USD
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor RDY genereren…
Openen
US$ 13,00
Hoog
US$ 13,07
Laag
US$ 12,94
Beursw.
10,81 mld.
Gem. vol.
3,19 mln.
Volume
2,79 mln.
Dividend
0,64%
Kwartaaldividend
US$ 0,02
Ex-dividenddatum
10 jul 2026
Koers/winst-verhouding
31,34
52 wk hoog
US$ 15,67
52 wk laag
US$ 11,36
WPA
US$ 0,42
Bèta
0,30
Uitstaande aandelen
834,64 mln.
Aantal medewerkers
28K
Openen
US$ 13,00
Hoog
US$ 13,07
Laag
US$ 12,94
Beursw.
10,81 mld.
Gem. vol.
3,19 mln.
Volume
2,79 mln.
Dividend
0,64%
Kwartaaldividend
US$ 0,02
Ex-dividenddatum
10 jul 2026
Koers/winst-verhouding
31,34
52 wk hoog
US$ 15,67
52 wk laag
US$ 11,36
WPA
US$ 0,42
Bèta
0,30
Uitstaande aandelen
834,64 mln.
Aantal medewerkers
28K
Nieuwsartikelen
Van webbronnen en nieuwspartners
MarketBeat
·
13 uur geleden
Dr. Reddy's Laboratories (NYSE:RDY) Stock Rating Raised to "Hold" at Wall Street Zen
ad-hoc-news.de
·
2 dagen geleden
Dr Reddy reports three FDA observations: what it means for Dr Reddy stock
TipRanks
·
3 dagen geleden
Dr. Reddy’s Receives USFDA Form 483 After Pre-Approval Inspection at Visakhapatnam Plant
Stock Titan
·
3 dagen geleden
An FDA pre-approval inspection ends with observations at Dr. Reddy’s (RDY) Visakhapatnam plant.
Profiel
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Over Dr Reddy's Laboratories Ltd
CEOErez Israeli
Medewerkers27,5K
Opgericht1984
HoofdkantoorHaiderabad, Andhra Pradesh, India
Sector-
Websitedrreddys.com